Actively Recruiting

Phase 1
Age: 18Years - 45Years
All Genders
Healthy Volunteers
NCT06859281

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Led by Valenta Pharm JSC · Updated on 2025-07-10

24

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to evaluate the safety, tolerability, and pharmacokinetic profile of the Grammidin, a metered dose topical spray, compared to Grammidin lozenges following single administration in healthy volunteers .

CONDITIONS

Official Title

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Who Can Participate

Age: 18Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent form prior to any study-related procedures
  • Male or female aged 18 to 45 years inclusive
  • Verified healthy status with no clinically significant abnormalities
  • Blood pressure: systolic 99-129 mm Hg, diastolic 70-89 mm Hg
  • Heart rate between 60 and 89 beats per minute
  • Respiratory rate between 12 and 20 breaths per minute
  • Body temperature from 36.0�b0C to 36.9�b0C
  • Body mass index between 18.5 and 30 kg/m�b2; minimum weight �b1 55 kg for men and �b1 45 kg for women
  • Consent to use effective contraceptive methods during the study and for 30 days after completion; negative pregnancy test for women of childbearing potential
Not Eligible

You will not qualify if you...

  • History of clinically significant allergies or hypersensitivity to study drugs
  • Drug intolerance to active or excipient substances in study drugs
  • Chronic diseases affecting kidneys, liver, gastrointestinal, cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, immune systems, skin, blood, or eyes
  • Oral mucosa lesions such as aphthous stomatitis or herpes
  • Prior gastrointestinal surgery except appendectomy more than 1 year ago
  • Conditions affecting drug absorption, distribution, metabolism, or excretion
  • Acute infections within 4 weeks before screening
  • Use of medications affecting hemodynamics or liver function within 2 months before screening
  • Regular medication use within 2 weeks or single use within 7 days before screening
  • Blood or plasma donation within 3 months before screening
  • Use of hormonal contraceptives within 2 months before screening
  • Depot medication injections within 3 months before screening
  • Pregnancy or lactation; positive pregnancy test
  • Unprotected sexual intercourse with unsterilized male partner within 30 days prior to drug administration
  • Participation in other clinical studies within 3 months prior or concurrent
  • Alcohol consumption over 10 units per week in the last month or history of substance abuse
  • Smoking more than 10 cigarettes per day currently or in past 6 months; unwillingness to refrain from smoking during hospitalization
  • Consumption of alcohol, caffeine, or xanthine products within 7 days prior to drug intake
  • Consumption of citrus fruits, cranberries, rose hips, St. John's wort products within 7 days prior to drug intake
  • Dehydration within 24 hours prior to drug intake
  • Positive tests for HIV, syphilis, hepatitis B or C, SARS-CoV-2
  • ECG abnormalities
  • Positive urine tests for narcotics or potent medications
  • Positive breath alcohol test
  • Planned hospitalization other than study-related
  • Inability or unwillingness to comply with protocol or dietary restrictions
  • Membership in vulnerable populations or other conditions preventing study participation
  • Dental procedures within 3 weeks prior to screening
  • Other investigator judgment reasons preventing participation or causing withdrawal

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Limited Liability Company "Research Center Eco-Safety"

Saint Petersburg, Russia, 196143

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers | DecenTrialz